Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain momentum from improving non-medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.
Cardinal Health (CAH) Ties Up to Deliver Products Via Drones
by Zacks Equity Research
Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2022 results benefit from strength in the Dental and Animal Health segments.
Align (ALGN) Gains From Increased Case Shipment Amid FX Woes
by Zacks Equity Research
Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
by Zacks Equity Research
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Here's Why Investors Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.
Stryker (SYK) to Boost Presence in China Via Digital Healthcare
by Zacks Equity Research
Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.
Here's Why Investors Should Retain CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.
Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
PerkinElmer (PKI) Unveils GC Platform to Simplify Lab Operations
by Zacks Equity Research
PerkinElmer's (PKI) newly introduced next-generation, automated GC platform can help simplify lab operations and offer excellent precision for high throughput environments.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment toward understanding the venous system. However, dependency on the wide adoption of products is a woe.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.